Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare cancers? drug combo shows promise in early trial

NCT ID NCT01396408

Ongoing Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sunitinib and temsirolimus
What this could lead to
If successful, this could provide a treatment option to shrink or stabilize advanced rare tumors for a period of time.
What could go wrong
This is a small, early-phase trial with no cure expected. The drugs may not work for all rare tumor types, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal cortex carcinoma angiosarcoma endometrial clear cell adenocarcinoma Ewing sarcoma familial medullary thyroid carcinoma fibrolamellar hepatocellular carcinoma hemangioblastoma hemangiopericytoma ovarian clear cell cancer paraganglioma pheochromocytoma thymic carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED RARE TUMOURS

Contacts and locations

Locations

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, S4T 7T1, Canada

  • BCCA - Cancer Centre for the Southern Interior

    Kelowna, British Columbia, V1Y 5L3, Canada

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, V5Z 4E6, Canada

  • CHU Sainte-Justine

    Montreal, Quebec, H3T 1C5, Canada

  • CHUM - Hopital Notre-Dame

    Montreal, Quebec, H2L 4M1, Canada

  • CancerCare Manitoba

    Winnipeg, Manitoba, R3E 0V9, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2, Canada

  • Hospital for Sick Children

    Toronto, Ontario, M5G 1X8, Canada

  • Izaak Walton Killam (IWK) Health Centre

    Halifax, Nova Scotia, B3K 6R8, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, L8V 5C2, Canada

  • London Regional Cancer Program

    London, Ontario, N6A 4L6, Canada

  • McGill University - Dept. Oncology

    Montreal, Quebec, H2W 1S6, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, K1H 8L6, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, S7N 4H4, Canada

  • Tom Baker Cancer Centre

    Calgary, Alberta, T2N 4N2, Canada

  • Univ. Health Network-Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.